Clinical trials: Cushing Syndrome, active
Hyperaldosteronism, Hypercortisolism
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works.
- Conditions
- Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
- Trial name
- NCT06246357
- Testing
- [68Ga]Ga-PentixaFor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing Disease
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Background: The pituitary gland produces hormones. A tumor in this gland can cause it to produce too much of the hormone cortisol. Too much cortisol in the body causes Cushing disease. This disease causes many problems.
- Trial name
- NCT03831958
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Type 2 Diabetes, Cortisol Excess
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol.
- Trial name
- CAPTAIN-T2D (NCT07296484)
- Testing
- clofutriben
- Where
- 61 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Sparrow Pharmaceuticals
ACTH, Cushing's Syndrome
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess.
- Trial name
- NCT02019706
- Testing
- DOTATATE PET-CT, F-DOPA PET CT, CT scan
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Endocrine Diseases
Evaluation of Adults With Endocrine and Metabolic-Related Conditions
Background: There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes.
- Trial name
- NCT02830308
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
- Trial name
- NCT06106295
- Testing
- Metyrapone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
- Trial name
- NCT07138274
- Testing
- Metyrapone 250 mg Oral Tablets
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Cushing Syndrome
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per…
- Trial name
- NCT04543253
- Testing
- MUSE biofeedback
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Mayo Clinic
Endogenous Cushing Syndrome, Adrenal Insufficiency
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace…
- Conditions
- Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
- Trial name
- NCT06430528
- Testing
- Osilodrostat
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan
Cushing Syndrome
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
Background: Cushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol.
- Trial name
- NCT06635629
- Testing
- Desmopressin, Dexamethasone
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypercortisolism, Type 2 Diabetes (T2DM)
Salivary Cortisol and Hypercortisolism in Type 2 Diabetes
The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies.
- Trial name
- NCT07156370
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai 6th People's Hospital
Diabetes, Obesity & Overweight
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or…
- Conditions
- Diabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases
- Trial name
- SARC-ENDO (NCT07703683)
- Testing
- GLP-1 Receptor Agonists
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Adult Glucocorticoid Excess, Adult Adrenal Insufficiency
Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)
The excess of glucocorticoid, whether endogenous or exogenous, results in Cushing's syndrome, associating a particular distribution of fats (accumulation in the face and trunk), a decrease in the thickness of the muscles…
- Trial name
- CUSHINGOMICS (NCT04840693)
- Testing
- Biological samples, Complications
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Aldosteronism, Aldosterone-Producing Adenoma
Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism
In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous…
- Conditions
- Primary Aldosteronism, Aldosterone-Producing Adenoma, Hypercortisolism
- Trial name
- NCT05368090
- Testing
- EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation, EUS-RFA of left adrenal tumour in PA, "debulking group", EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Haukeland University Hospital
Adrenocortical Carcinoma, Cushing's Syndrome
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice.
- Trial name
- NCT00457587
- Where
- Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Wuerzburg
Adrenal Tumors, Adrenocortical Carcinoma
Adrenal Tumors - Pathogenesis and Therapy
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates…
- Conditions
- Adrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome
- Trial name
- NCT00669266
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Wuerzburg
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP